11.30
price up icon0.62%   0.07
after-market Dopo l'orario di chiusura: 11.30
loading
Precedente Chiudi:
$11.23
Aprire:
$11.26
Volume 24 ore:
70,236
Relative Volume:
0.26
Capitalizzazione di mercato:
$565.02M
Reddito:
$62.02M
Utile/perdita netta:
$-45.65M
Rapporto P/E:
-12.28
EPS:
-0.92
Flusso di cassa netto:
$-9.60M
1 W Prestazione:
-3.00%
1M Prestazione:
+6.91%
6M Prestazione:
+16.86%
1 anno Prestazione:
+12.10%
Intervallo 1D:
Value
$11.26
$11.35
Intervallo di 1 settimana:
Value
$11.16
$11.88
Portata 52W:
Value
$7.44
$11.88

Theravance Biopharma Inc Stock (TBPH) Company Profile

Name
Nome
Theravance Biopharma Inc
Name
Telefono
650-808-6000
Name
Indirizzo
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Name
Dipendente
97
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-12
Name
Ultimi documenti SEC
Name
TBPH's Discussions on Twitter

Confronta TBPH con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
TBPH
Theravance Biopharma Inc
11.30 561.51M 62.02M -45.65M -9.60M -0.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-08-06 Downgrade Leerink Partners Outperform → Market Perform
2024-04-12 Iniziato BTIG Research Buy
2024-01-08 Downgrade Evercore ISI Outperform → In-line
2022-05-23 Iniziato SVB Leerink Outperform
2021-11-05 Aggiornamento JP Morgan Underweight → Neutral
2021-09-15 Downgrade JP Morgan Overweight → Underweight
2021-08-25 Downgrade Morgan Stanley Overweight → Underweight
2021-08-24 Downgrade Cowen Outperform → Market Perform
2020-10-14 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2020-07-07 Iniziato JP Morgan Overweight
2020-06-15 Iniziato Morgan Stanley Equal-Weight
2020-05-13 Iniziato Cowen Outperform
2020-01-08 Reiterato H.C. Wainwright Buy
2019-11-06 Aggiornamento Robert W. Baird Underperform → Neutral
2019-10-29 Iniziato H.C. Wainwright Buy
2018-03-29 Ripresa Piper Jaffray Overweight
2017-08-17 Iniziato Evercore ISI Outperform
2017-06-16 Iniziato Cantor Fitzgerald Overweight
2017-05-11 Reiterato Needham Buy
2016-12-21 Iniziato Needham Buy
2016-11-03 Iniziato Piper Jaffray Overweight
2016-10-12 Downgrade Robert W. Baird Neutral → Underperform
2016-08-03 Downgrade BofA/Merrill Neutral → Underperform
2016-06-20 Iniziato Guggenheim Buy
2016-06-20 Reiterato Leerink Partners Outperform
2016-05-12 Iniziato Leerink Partners Outperform
2016-05-05 Downgrade BofA/Merrill Buy → Neutral
2015-02-03 Aggiornamento Robert W. Baird Underperform → Neutral
Mostra tutto

Theravance Biopharma Inc Borsa (TBPH) Ultime notizie

pulisher
Jul 23, 2025

What analysts say about Theravance Biopharma Inc. stockExplosive trading growth - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Theravance Biopharma Inc. Stock Analysis and ForecastExceptional trading results - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Theravance Biopharma to Participate in an Upcoming Investor Conference - Citizen Tribune

Jul 23, 2025
pulisher
Jul 22, 2025

Is Theravance Biopharma Inc. a good long term investmentFast-track wealth growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Theravance Biopharma Inc. stock priceConsistent triple-digit returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

How Theravance Biopharma Inc. stock performs during market volatilitySecure Your Capital Strategy - Newser

Jul 22, 2025
pulisher
Jul 17, 2025

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail

Jul 17, 2025
pulisher
Jul 16, 2025

Theravance Biopharma SVP Farnum sells $113,869 in stock By Investing.com - Investing.com Nigeria

Jul 16, 2025
pulisher
Jul 16, 2025

Theravance Biopharma SVP Farnum sells $113,869 in stock - Investing.com

Jul 16, 2025
pulisher
Jul 16, 2025

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - The Globe and Mail

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Theravance Biopharma Inc. stock price move sharplyStrategic High Profit Opportunities - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Theravance Biopharma Inc. stock attracts strong analyst attentionFree Daily Stock Market Updates - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma - Insider Monkey

Jul 15, 2025
pulisher
Jul 15, 2025

Brokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) Target Price at $16.60 - Defense World

Jul 15, 2025
pulisher
Jul 14, 2025

Theravance Biopharma SVP Sells 7,000 Shares for $78,000 on July 14, 2025. - AInvest

Jul 14, 2025
pulisher
Jul 13, 2025

Theravance higher as China approves Viatris-partnered COPD therapy - MSN

Jul 13, 2025
pulisher
Jul 12, 2025

Theravance Biopharma (NASDAQ:TBPH) Downgraded to “Hold” Rating by Wall Street Zen - Defense World

Jul 12, 2025
pulisher
Jun 30, 2025

Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from Russell 2000 Defensive Index - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Theravance Biopharma, Inc.(NasdaqGM: TBPH) added to Russell Microcap Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 28, 2025

Theravance Biopharma (NASDAQ:TBPH) Given New $25.00 Price Target at BTIG Research - Defense World

Jun 28, 2025
pulisher
Jun 27, 2025

TBPH Stock Price Target Increased Following Milestone Payment | TBPH Stock News - GuruFocus

Jun 27, 2025
pulisher
Jun 27, 2025

JonesTrading Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛

Jun 27, 2025
pulisher
Jun 26, 2025

Theravance Biopharma price target raised to $25 by BTIG on China approval - Investing.com

Jun 26, 2025
pulisher
Jun 25, 2025

Is Theravance Biopharma, Inc. technically bullish or bearish? - MarketsMojo

Jun 25, 2025
pulisher
Jun 18, 2025

Theravance Biopharma (NASDAQ:TBPH) Now Covered by Jones Trading - Defense World

Jun 18, 2025
pulisher
Jun 18, 2025

Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by Jones Trading - Defense World

Jun 18, 2025
pulisher
Jun 17, 2025

Theravance Biopharma (TBPH) Receives New Analyst Coverage with a Buy Rating | TBPH Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

(TBPH) Proactive Strategies - news.stocktradersdaily.com

Jun 17, 2025
pulisher
Jun 16, 2025

Theravance Biopharma (TBPH) Gains Buy Rating with Promising Drug Prospects | TBPH Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 09, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 32,534 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Jun 09, 2025
pulisher
Jun 06, 2025

Theravance and Mylan settle patent dispute with Eugia Pharma - MSN

Jun 06, 2025
pulisher
Jun 06, 2025

theravance biopharma settles patent litigation with eugia pharma By Investing.com - Investing.com South Africa

Jun 06, 2025

Theravance Biopharma Inc Azioni (TBPH) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Capitalizzazione:     |  Volume (24 ore):